EC Number   |
General Information |
Reference |
|---|
   3.4.21.68 | evolution |
human tissue plasminogen activator belongs to the serine protease family |
753083 |
| 3.4.21.68 | malfunction |
altered tPA activity levels in mouse models of Alzheimer's disease and spinocerebellar ataxia type-1, SCA1. Decreased tPA activity is detected in the cortex and subcortex of Alzheimer's disease mice, whereas increased tPA activity is found in the cerebellum of SCA1 mice |
-, 718064 |
| 3.4.21.68 | malfunction |
decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient -/- mice, the tPA-/- mice demonstrate an enhanced tendency to actively explore and engage in behaviors involving more exposure in the open field, O-maze and elevated plus maze |
707932 |
| 3.4.21.68 | malfunction |
the concentrations of t-PA and PAI-1 in the plasma have been identified as variables contributing to the risk of arterial thrombosis |
707027 |
| 3.4.21.68 | malfunction |
tissue-plasminogen activator and plasminogen activator inhibitor, PAI-1, polymorphisms play a role in myocardial infarction within the Pakistanian population. The PAI-1 gene polymorphism has a gender specific role in the female myocardial infarction patients |
718098 |
| 3.4.21.68 | malfunction |
tPA-deficient ALBPLG1 mice show no difference in survival, bacterial dissemination or the pathology of GAS infection in the absence of tPA in AlbPLG1/tPA-/- mice compared to wild-type AlbPLG1 mice |
754645 |
| 3.4.21.68 | metabolism |
the plasminogen-plasmin (PLG-PLA) system plays a role in thrombolysis, being capable of degrading blood clots. THe system consists of plasminogen, the inactive zymogen produced principally in the liver, its activators (tissue plasminogen activator, tPA and uroquinase plasminogen activator, uPA (EC 3.4.21.73)), their inhibitors (belonging to the serpin gene superfamily, named PAI-1, PAI-2, PAI-3 and protease nexin I), the uPA receptor and, finally, the active enzyme plasmin and its inhibitor, alpha-antiplasmin (alpha-PL). Apart from its fibrinolytic function, the PLG-PLA system is important in degrading the extracellular matrix in multiple tissues contributing to cell migration, angiogenesis, tissue repair and remodelling or tumour invasion |
-, 755364 |
| 3.4.21.68 | metabolism |
tissue-type plasminogen activator functions as the main activator of the fibrinolytic process in the intravascular compartment |
710120 |
| 3.4.21.68 | metabolism |
urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) are two serine proteases that contribute to initiating fibrinolysis by activating plasminogen. uPA is also an important tumour-associated protease due to its role in extracellular matrix remodelling |
753267 |
| 3.4.21.68 | more |
alteplase is the full-length recombinant human TPA, while reteplase, K2P, is the domain deletion mutant comprising only the Kringle-2 domain and protease domain of TPA. Reteplase shows a better protective effect than alteplase, suggesting that F, P, or K1 domain in TPA diminishes the brain-protective effect |
-, 717679 |
